Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "non-pegylated liposomal doxorubicin" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-4 z 4
    Tytuł:
    The young breast cancer patient therapy – new opportunities, new challenges
    Autorzy:
    Załuska-Kusz, Joanna
    Kufel-Grabowska, Joanna
    Powiązania:
    https://bibliotekanauki.pl/articles/1035689.pdf
    Data publikacji:
    2019
    Wydawca:
    Medical Education
    Tematy:
    breast cancer in young patient
    metastatic disease
    non-pegylated liposomal doxorubicin
    ribociclib
    Opis:
    The paper describes the case of a 31-year-old female patient with breast cancer with the abdominal metastases. This disease in young people usually has a more aggressive biological subtype, which significantly worsens the prognosis. In this patient aggressive treatment was used. It was effective and did not cause severe or long-term complications.
    Źródło:
    OncoReview; 2019, 9, 2; 51-54
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Efficacy and safety of non-pegylated liposomal doxorubicin in metastatic breast cancer therapy
    Autorzy:
    Wójcik, Elżbieta
    Kufel-Grabowska, Joanna
    Gierba-Tomczyk, Joanna
    Powiązania:
    https://bibliotekanauki.pl/articles/1062503.pdf
    Data publikacji:
    2017
    Wydawca:
    Medical Education
    Tematy:
    breast cancer
    non-pegylated liposomal doxorubicin
    treatment
    Opis:
    Breast cancer is the most frequently diagnosed female cancer in Poland (over 17,500 women). Anthracyclines have become one of the most important drugs in breast cancer systemic treatment. In the treatment of metastatic disease combination chemotherapy with doxorubicin provides the objective response rate of 60–85%, and the median time of progression-free survival is about 12 months. Non-pegylated liposomal doxorubicin (NPLD) in combination with cyclophosphamide is associated with a lower risk of cardiotoxicity, higher efficacy and more favourable toxicity profile as compared with conventional anthracycline regimes. Two cases of females patients treated with NPLD described in this article demonstrate the importance of the choice of chemotherapy, professional monitoring, early detection and treatment of adverse effects. Non-pegylated liposomal doxorubicin ordained in systemic treatment of stage IV breast cancer prolongs survival and enhances the quality of life. It is a reasonable option for palliative therapy.
    Źródło:
    OncoReview; 2017, 7, 4; 162-167
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Non-pegylated liposomal doxorubicin plus capecitabine as first-line treatment in metastatic breast cancer
    Autorzy:
    Plecka, Piotr
    Powiązania:
    https://bibliotekanauki.pl/articles/1064811.pdf
    Data publikacji:
    2016
    Wydawca:
    Medical Education
    Tematy:
    breast cancer
    chemotherapy
    new regimen
    non-pegylated liposomal doxorubicin
    Opis:
    Purpose: To determine the toxicity and efficacy profile of non-pegylated doxorubicin in combination with capecitabine administered according to LipAX regimen. Materials and methods: The analysis included 5 female patients undergoing first-line treatment for metastatic breast cancer. Patients received non-pegylated doxorubicin intravenously and oral capecitabine at usual doses used for monotherapy, until disease progression or unacceptable toxicity. Results: Patients received a total of 26 complete treatment cycles according to LipAX regimen. During treatment, 15 toxicities occurred, including 7 adverse events with grade 3 severity. Only two haematological toxicities were observed, and the other 13 were of a non-haematological nature. Only one patient experienced no adverse events. Apart from symptomatic treatment, the capecitabine dose was reduced twice and the non-pegylated doxorubicin once. Positive clinical outcomes were observed in 4 patients, and disease progression was reported in the case of 1 patient in the course of the treatment. The median time to disease progression was 10.4 months, and the median overall survival was 34.2 months. During the 54-month follow-up, 4 of the patients died. The surviving patient continues treatment. Conclusions: Therapy according to the LipAX regimen was relatively well tolerated, however, since the majority of patients discontinued treatment due to adverse events, and not disease progression, an adequate reduction in the cytostatic doses should be considered. The use of the LipAX regimen may contribute to the achievement of long-term remission in some patients, a fact that encourages further studies on this form of therapy.
    Źródło:
    OncoReview; 2016, 6, 4; A193-198
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Therapy with liposomal doxorubicin in patients with advanced breast cancer after treatment with classical doxorubicin
    Autorzy:
    Kufel-Grabowska, Joanna
    Powiązania:
    https://bibliotekanauki.pl/articles/1065267.pdf
    Data publikacji:
    2015
    Wydawca:
    Medical Education
    Tematy:
    breast cancer
    complications of oncological therapy
    non-pegylated liposomal doxorubicin
    Opis:
    Breast cancer is the most common female cancer in the world and in Poland. The improvement of diagnostic and therapeutic methods has led to patients’ longer life expectancy. It has also made breast cancer a chronic disease, increasing the risk of late side effects of oncological therapy. More cardiovascular diseases are diagnose in patients over 65 with an oncological history than in those without it and therefore much effort must be made to maximise effectiveness of the therapy with as few side effects as possible. The article presents two breast cancer patients treated with big doses of liposomal doxorubicin with a good response and almost no side effects.
    Źródło:
    OncoReview; 2015, 5, 3; A103-108
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-4 z 4

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies